Title: Healthcare resource utilization, cost and clinical outcomes in patients diagnosed with COPD initiating tiotropium bromide/olodaterol versus fluticasone furoate/umeclidinium/vilanterol based on exacerbation history.
Citation: Int J Chron Obstruct Pulmon Dis
2023;18:625–641.
Country: USA | Indication: COPD
This is a pharma-supported study
Scan to access the publication or visit
http://tago.ca/37155497
http://tago.ca/37155497